Latest News & Features
Americas
Genetic diagnostic company Myriad Genetics and other patent holders have been denied a motion for a preliminary injunction that would have kept rival company Ambry Genetics from selling its own test for BRCA gene mutations. 12 March 2014
Europe
The Unified Patent Court has clarified its opt-out scheme, making clear that when a European patent has been opted out of the scheme, its associated supplementary protection certificate will follow. 11 March 2014
Americas
Texas-based biopharmaceutical company Caisson Biotech has expanded its partnership with diabetes therapy maker Novo Nordisk by giving Novo exclusive rights to commercialise an insulin treatment that uses Caisson’s drug delivery technology. 11 March 2014
Big Pharma
While the political will exists for the introduction of the Unified Patent Court next year, much more still needs to be done, according to Adam Cooke, a partner in DLA Piper's IP and technology group. 5 March 2014
Big Pharma
A key concern for lawyers and in-house counsels practising in the pharmaceutical industry is the disclosure of clinical data, according to the co-chairs of DLA Piper's Global Life Sciences sector, Bonella Ramsay and John Dougherty. 4 March 2014
Asia
The Delhi High Court has dismissed Teva’s action to stop Hyderabad-based Natco Pharma from marketing a generic version of its blockbuster multiple sclerosis drug Copaxone (glatiramer acetate). 3 March 2014
Asia
While Western pharmaceutical companies struggle to enforce their IP rights in India, Roche has taken an unorthodox but surprisingly effective stance, as Debashish Banerjee and Shukadev Khuraijam explain. 28 February 2014
Europe
Recent CJEU decisions on SPCs have brought little clarity to the meaning of ‘product’, and a recent Advocate General opinion in Bayer CropScience AG threatens to muddy the waters even further, says Paul England. 28 February 2014
Europe
A new referral to the CJEU should shed light on the extent of the so-called Bolar exemption in Europe, says Bernd Allekotte. 28 February 2014
Americas
Apexigen uses antibodies derived from rabbits to develop therapies for diseases that are difficult to treat. LSIPR found out how it protects its novel technologies. 28 February 2014